2016 Annual Report

The Exelixis 2016 Annual Report highlights the important role that teamwork plays in oncology, from discovering and developing a new medicine to the actual treatment process itself.

Letter to Stockholders

Exelixis President and CEO Michael M. Morrissey, Ph.D., provides an overview of the company’s performance in 2016, including clinical and business milestones for the company and the Exelixis-discovered compounds cabozantinib and cobimetinib.

View the Letter to Stockholders

 

Teaming Up to Help Patients

Learn more about the launch of the latest Exelixis medicine, and see how the Exelixis team and the broader oncology community both place a particular emphasis on collaboration.

Learn More